Biomarkers, myocardial fibrosis and co-morbidities in heart failure with preserved ejection fraction: an overview

Archives of Medical Science : AMS
Marta Michalska-KasiczakMaciej Banach

Abstract

The prevalence of heart failure with preserved ejection fraction (HFpEF) is steadily increasing. Its diagnosis remains difficult and controversial and relies mostly on non-invasive echocardiographic detection of left ventricular diastolic dysfunction and elevated filling pressures. The large phenotypic heterogeneity of HFpEF from pathophysiologic al underpinnings to clinical manifestations presents a major obstacle to the development of new therapies targeted towards specific HF phenotypes. Recent studies suggest that natriuretic peptides have the potential to improve the diagnosis of early HFpEF, but they still have significant limitations, and the cut-off points for diagnosis and prognosis in HFpEF remain open to debate. The purpose of this review is to present potential targets of intervention in patients with HFpEF, starting with myocardial fibrosis and methods of its detection. In addition, co-morbidities are discussed as a means to treat HFpEF according to cut-points of biomarkers that are different from usual. Biomarkers and approaches to co-morbidities may be able to tailor therapies according to patients' pathophysiological needs. Recently, soluble source of tumorigenicity 2 (sST2), growth differentiation factor 15 (GD...Continue Reading

Citations

Jan 5, 2019·American Journal of Respiratory and Critical Care Medicine·Harm Jan Bogaard, Norbert F Voelkel
Mar 9, 2019·Cardiac Failure Review·Sunil K Nadar, Mohammad Mujtaba Shaikh
Sep 13, 2019·Circulation. Genomic and Precision Medicine·Sharon CresciMatthew J Wolf
Mar 15, 2020·Heart Failure Reviews·Bianca Olivia Cojan-MinzatLucia Agoston-Coldea
Feb 18, 2020·Chemistry : a European Journal·Anna NotaroGilles Gasser
Dec 31, 2019·European Heart Journal Supplements : Journal of the European Society of Cardiology·Alessia LenaMarkus S Anker
Sep 25, 2018·International Journal of Analytical Chemistry·Qingxin LiuChunyi Tong
May 31, 2019·International Journal of Molecular Sciences·Daniela Maria TanaseMariana Floria
Jun 18, 2020·Frontiers in Medicine·Katsunori YanaiYoshiyuki Morishita
Jan 17, 2020·International Journal of Molecular Sciences·So-Hyeon Hong, Kyung Mook Choi
Nov 6, 2020·Oxidative Medicine and Cellular Longevity·Andrea GonzalezClaudio Cabello-Verrugio
Feb 18, 2021·Irish Journal of Medical Science·Anna ChudaAgata Bielecka-Dabrowa
May 9, 2021·European Journal of Preventive Cardiology·Francesco GentileAlberto Giannoni
Nov 20, 2021·Medicine·Jie YangChuan-Hua Yang

❮ Previous
Next ❯

Methods Mentioned

BETA
imaging techniques
reverse transcription PCR
antisense oligonucleotides

Software Mentioned

TOPCAT
OPTIMIZE

Related Concepts

Related Feeds

Cardiac Cachexia

Cardiac cachexia is a syndrome associated with the progressive loss of muscle and fat mass. It most commonly affects patients with heart failure and can significantly decrease the quality of life and survival in these patients. Here is the latest research on cardiac cachexia.